MDM2 regulates estrogen receptor $\alpha$ and estrogen responsiveness in breast cancer cells

Kyounghyun Kim$^{1,2}$, Robert Burghardt$^{3}$, Rola Barhoumi$^{3}$, Syng-ook Lee$^{2}$, Xinyi Liu$^{4}$ and Stephen Safe$^{1,2}$

$^1$Department of Veterinary Physiology and Pharmacology, Texas A&M University, 4466 TAMU, Veterinary Research Building 410, College Station, Texas 77843-4466, USA
$^2$Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas 77030, USA
Departments of $^3$Veterinary Integrative Biosciences and $^4$Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843, USA

(Correspondence should be addressed to S Safe at Department of Veterinary Physiology and Pharmacology, Texas A&M University; Email: ssafe@cvm.tamu.edu)

Abstract

Murine double minute clone 2 (MDM2) is a multifunctional protein, which modulates nuclear receptor-mediated transactivation. In this study, we show that MDM2 significantly enhanced estrogen receptor $\alpha$ (ER$\alpha$) and ER$\alpha$/specificity protein-mediated transactivation in MCF-7 and ZR-75 breast cancer cells. This was demonstrated by both MDM2 overexpression and knockdown experiments by RNA interference. ER$\alpha$ interacted with wild-type MDM2 and deletion mutants of MDM2 containing amino acids 1–342 (C-terminal deletion) and 134–490 (N-terminal deletion), but not 134–342. In contrast, only wild-type but not mutant MDM2 enhanced ER$\alpha$-mediated transactivation. Protein–protein interactions in vitro were 17$\beta$-estradiol (E$_2$) independent, whereas fluorescent resonance energy transfer experiments in living cells showed that E$_2$ enhanced ER$\alpha$–MDM2 interactions. Subsequent RNA interference and mammalian two-hybrid experiments suggested that MDM2 did not directly interact with endogenous coactivators such as the steroid receptor coactivators but played a role in enhancing ER$\alpha$-mediating gene expression and estrogen responsiveness through interactions with ER$\alpha$.

Journal of Molecular Endocrinology (2011) 46, 67–79

Introduction

Murine double minute clone 2 (MDM2) was initially cloned from a transformed 3T3 cell line, and later identified as a p53-interacting protein (Cahilly-Snyder et al. 1987, Fakharzadeh et al. 1991, Momand et al. 1992). It was subsequently shown that overexpression of MDM2 resulted in cell transformation and oncogenicity and this was due, in part, to suppression of the tumor suppressor gene p53. The complex interrelationships between MDM2 and p53 have been extensively investigated (Levav-Cohen et al. 2005, Brooks & Gu 2006). MDM2 exhibits E3-ubiquitin ligase activity, which increases ubiquitination of p53 and, in combination with other factors, the resulting proteasome-dependent degradation of p53 decreases expression of this tumor suppressor gene under nonstressed conditions (Ashcroft et al. 1999, Kubboutat et al. 1999). The role of MDM2 in regulating p53 expression is also apparent in transgenic mice where MDM2 knockout animals exhibit embryolethality, which is reversed by inactivation of p53 (Jones et al. 1995, Montes de Oca Luna et al. 1995, de Rzieres et al. 2000). Under conditions of cellular stress, the physical and functional interactions of MDM2 and p53 are inhibited, thereby allowing p53 to activate gene expression pathways, such as inhibition of cell cycle progression and induction of apoptosis, which allow the cells to respond to stressors. The interactions between p53 and MDM2 are complex and are modified under various conditions and in a cell/tissue context-dependent manner (Brooks & Gu 2006).

Since MDM2 inhibits p53 function as a tumor suppressor gene, it is not surprising that expression of MDM2 plays a role in cancer and in cancer prognosis (Levav-Cohen et al. 2005). Overexpression of MDM2 is frequently observed in many different cancers; however, the prognosis for patients in which MDM2 levels are high is dependent on multiple factors including the type of tumor and its origin. For example, MDM2 overexpression through gene amplification in gliomas predicts poor survival (Korkolopoulou et al. 1997, Rainov et al. 1997, Schiebe et al. 2000), whereas overexpression through gene amplification in breast cancer is observed only in estrogen receptor (ER)$^+$-positive tumors for which there is a good prognosis for survival (Bueso-Ramos et al. 1996, Lukas et al. 2001, Hori et al. 2002). The variability of MDM2 as a prognostic indicator for cancer survival is complex and may be due to interactions with other unknown factors.

A number of p53-independent functions of MDM2 have been identified and show that this protein can modify different signaling pathways. MDM2 interacts...
with and inhibits the function of retinoblastoma (Rb) protein and other Rb family members (Hsieh et al. 1999) and this affects E2F1-DP1-mediated responses (Martin et al. 1995) and also enhances the transcriptional activation of cyclin A (Leveillard & Wasylyk 1997). MDM2 also modulates ligand-dependent activation of several steroid hormone receptors including the glucocorticoid receptor, androgen receptor, and ER (Liu et al. 2000, Saji et al. 2001, Sengupta & Wasylyk 2004). MDM2 overexpression in MCF-7 human breast cancer cells enhances their estrogen-dependent growth and, in p53-deficient Saos-2 osteosarcoma cells and MCF-7 cells, MDM2 enhances 17β-estradiol (E2)-dependent activation of a construct containing an estrogen response element (ERE) insert (Saji et al. 2001).

This study shows by RNA interference that MDM2 enhances E2-dependent growth and transactivation in breast cancer cells using constructs containing three tandem EREs or GC-rich motifs (pSP13) activated by ERα or ERβ/SP1 respectively. MDM2 overexpression also coactivates ERα and ERβ/SP1, and the results suggest that the coactivation response is primarily through direct interactions of MDM2 with ERα and MDM2-dependent enhanced interactions of ERα with coactivators.

Materials and methods

Cell lines, chemicals, and biochemicals

The ZR-75 (ZR-75.1), MCF-7, and T47D human breast cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in RPMI 1640 or DMEM (Sigma) supplemented with 5 or 10% FBS and the medium was further supplemented with antibiotic/antimycotic solution (Sigma). Prior to transfection, RPMI or DMEM medium was replaced by DMEM/F-12 (Sigma). The cells were maintained at 37°C with a humified CO2/air (5:95) mixture. Small inhibitory RNA (siRNA) duplexes for MDM2 (siMDM2), p53 (sip53), luciferase (siGL2), and other appropriate expression plasmids were generated by PCR amplification (Duke University, Durham, NC, USA). The ZR-75 (ZR-75.1), MCF-7, and T47D human breast cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in RPMI 1640 or DMEM (Sigma) supplemented with 5 or 10% FBS and the medium was further supplemented with antibiotic/antimycotic solution (Sigma). Prior to transfection, RPMI or DMEM medium was replaced by DMEM/F-12 (Sigma) supplemented with charcoal-stripped 10% FBS. Cells were maintained at 37°C with a humified CO2/air (5:95) mixture. Small inhibitory RNA (siRNA) duplexes for MDM2 (siMDM2), p53 (sip53), luciferase (siGL2), and the scrambled siRNA (siCT) were purchased either from Ambion (Austin, TX, USA) or Sigma–Aldrich. The sequence for siGL2: 5'-CGU ACG CGG AAU ACU UCG ATT-3'; for siMDM2: 5'-GAA CAA GAG ACC CTG GTT A-3'; for sip53: 5'-GAG GUU GGC UCU GAC UGU A-3'; for scrambled RNA (siCT): 5'-ACU CUA UCU GCA CGC UGA CTT-3'.

Plasmids and cloning

pERE3, pSP13, pCAD, and pE2F1 were previously generated in our laboratory. pcDNA-MDM2 (490 aa) was kindly provided by Dr Lane (University of Dundee, UK). The MDM2 deletion mutants (135–490 aa, 135–342 aa, and 1–342 aa) were generated by cloning MDM2 deletion mutant amplified PCR products into EcoRI/XhoI sites of pcDNA3.1. His plasmid. MDM2 deletion mutants were generated by PCR using following primer sets: 1–342 aa: (F) 5'-GAA TTC ATG TGC AAT ACC AAC ATG TC-3', (R) 5'-CTC GAG TTT TTC AGA GAT TTC CAC-3'; 135–490 aa: (F) 5'-GAA TTC CCT TTG CAA GCG CCA CCA G-3', (R) 5'-CTC GAG CTA GTT GAA GTA GT AGT TAG CAC-3'; 135–342 aa: (F) 5'-GAA TTC CCT TTG CAA GCG CCA CCA G-3', (R) 5'-CTC GAG TTG TTG AGA GAT TTG AAC CAC-3'. These generated Xpress-tagged expression plasmids were also used for in vitro coimmunoprecipitation assays. pmMDM2 and VP-MDM2 expression plasmids were generated by PCR amplification of MDM2 wild-type and cloned into EcoRI and HindIII sites of pM and VP16 vectors (Clontech). For ECFP-MDM2 vector generation, the amplified MDM2 PCR product was digested with EcoRI and XhoI, and cloned into CFP-C1 vector (Clontech). The GAL4-coactivator fusion plasmids pMSRC1, pMGRIpwt, and pMAIB1 were kindly provided by Dr Shigeaki Kato (University of Tokyo, Tokyo, Japan), and pMGRIP (LXXLL) (fused to the yeast GAL4 DBD) was obtained from Dr Donald McDonnell (Duke University, Durham, NC, USA).

Transient transfection assays

The cells were seeded into 12-well plates in phenol-free DMEM/F-12 supplemented with 5% charcoal-stripped FBS. After 24 h, cells were transfected by lipofectamine 2000 reagent (Invitrogen) with 250 ng of an appropriate reporter plasmid (pERE3, pSP13, pCAD, pE2F1, or GAL4-luciferase), 50 ng of a CMV β-galactosidase expression plasmid, and other appropriate expression plasmids (125 ng/well) (ERα, MDM2 wild-type and mutants (1–342 aa, 134–490 aa, and 134–490 aa)), pMERz, pMMDM2, VP-ERα, or VP-MDM2. Empty vectors or nonspecific (siCT) oligonucleotides were used as controls in all transfection experiments. After transfection for 24 h, cells were treated with Me2SO or 10 nmol/l E2 with 5% stripped serum media for 24 h. In cells transfected with siRNA(s), E2 was added after 36–48 h for accomplishing efficient knockdown of target gene. Cells were then harvested, and luciferase activity (relative to β-galactosidase activity) was determined. Normalized luciferase values were obtained by dividing the luciferase by the β-galactosidase activities for a given sample. The results are expressed as means ± S.E.M. for at least three separate experiments for each treatment group.

In vitro coimmunoprecipitation assay

Transcription Translation System (Promega Corp.). MDM2 wild-type and all mutants were Xpress tagged. \(^{35}\text{S}\)ERz (1 µl) and \(^{33}\text{S}\)-labeled MDM2 wild-type or deletion mutant protein (0.5 µl) were coincubated in coimmunoprecipitation buffer (sterilized PBS + 0.01% IGEPAL CA630) with E2 to give a final concentration of 100 nM E2. After incubation for 1 h at 4 °C, 25 µl of 50% slurry of protein G-sepharose beads (Amersham Biosciences) were added to the incubation solution, followed by incubation for 2 h on a rocker at 4 °C. Samples were then centrifuged and washed, the final pellet was boiled in 30 µl of 2× SDS sample buffer, and proteins were separated on a 8% SDS-PAGE and visualized by autoradiography.

Western blot analysis

Depletion of MDM2 protein was determined, 48 h after transfection with siRNA for MDM2, breast cancer cells were harvested with RIPA lysis buffer (1× PBS, 1% Nonidet P-40 or Igepal CA630, 0.5% sodium deoxycholate, 0.1% SDS, 1 mg/ml phenylmethylsulfonyl fluoride in isopropanol, aprotinin, and 100 nM sodium orthovanadate), and equal amounts of protein from each group were boiled with sample buffer and loaded onto 8% SDS-polyacrylamide gel. The membrane was blocked and probed with primary antibodies for MDM2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) O/N at 4 °C. Membrane was visualized using the ECL detection system (PerkinElmer Life Sciences, Boston, MA, USA).

Cell proliferation assay

MCF-7 or ZR-75 cells (5 × 10^4 per well) were plated into 12-well plates and allowed to attach for 24 h, and then cells were transfected with either control siRNA or MDM2 siRNA. After 24 h, the medium was changed to charcoal-stripped 5% FBS DMEM medium containing either vehicle (DMSO) or estrogen (10 nM). Fresh medium was added every 48 h. Cells were then trypsinized and counted at the indicated times using a Coulter Z1 particle counter. Each experiment was performed in triplicate and the results are expressed as means ± S.E.M. for each treatment group.

Quantitative RT-PCR

RNA was harvested from T47D cells using the RNeasy mini or micro kits (Qiagen). First-strand cDNA synthesis was performed with 1 µg RNA using Reverse Transcription kit from Promega. Real-time PCR was performed using SYBR Green PCR Master Mix reagent, the ABI PRISM 7000 sequence detection system, and software (Applied Biosystems, Foster City, CA, USA). The primer sets were for CAD: (F) 5' ACC ACG ACA CCT GAA AGA CC-3', (R) 5’-TAC TGG TGG AGG GTA GC-3'; for pS2: (F) 5’-CAC CAT GGA GAA CAG GTG A-3', (R) 5’-AGC CCT TAT TTG CAC ACT GG-3'; for cyclin D1: (F) 5’-CGA TGC CAA CCT CCG CAA CGA-3', (R) 5’-TGG CAC ACC TCC AGC ATC CA-3'; for β-actin: (F) 5’-GGG GTG TTG AAG GTC TCA AA-3'; for E2F1: (F) 5’-ATG TTT TCC TTG GCC CGT AG-3', (R) 5’-ATC TGT GGT GAG GTA TGA GA-3'.

Fluorescence resonance energy transfer analysis

The cells were grown in two-well Lab-Tek Chambered Coverglass slides (Nalge Nunc International, Rochester, NY, USA) in DME/F12 medium supplemented with 5% charcoal-stripped serum and then transfected with CFP-MDM2/YFP-ERz or CFP-SP1/YFP-ERz sets. All the procedures for measuring fluorescence resonance energy transfer (FRET) efficiency were previously described (Kim et al. 2005). Briefly, after transfection for 24 h, cells were put on the stage of a Bio-Rad 2000 MP microscope system (Bio-Rad Laboratories) equipped with a Nikon T#300 inverted microscope. The images were acquired between 5 and 15 min before and after the addition of 10 nM E2. FRET efficiency data were collected using two photon 820 nm excitation wavelength. Emission of CFP (CFP channel, donor wavelength) were collected using two photon 820 nm excitation wavelength. Emission of CFP (CFP channel, donor wavelength) were collected using two photon 820 nm excitation wavelength. Emission of CFP (CFP channel, donor wavelength) were collected using two photon 820 nm excitation wavelength. Emission of CFP (CFP channel, donor wavelength) were collected using two photon 820 nm excitation wavelength. Emission of CFP (CFP channel, donor wavelength) were collected using two photon 820 nm excitation wavelength.

Statistical analysis

Statistical differences between different treatments were determined using Student’s t-test or ANOVA (Fisher’s protected least significant difference), and the levels of significance are shown (P<0.05). The results are expressed as mean ± S.E.M. for at least three replicate determinations for each experiment.

Results

MDM2 enhances E2-dependent transactivation

Previous studies showed that E2 responsiveness was enhanced in MCF-7 cells overexpressing MDM2, and similar results were observed in Saos-2 cells transfected...
with ER\(\alpha\) and MDM2 expression plasmids and an ERE reporter construct (Saji et al. 2001). In this study, we first examined the effects of endogenous MDM2 on E\(\alpha\)-induced transactivation in ZR-75 breast cancer cells transfected with pERE\(_3\) (Fig. 1A) or pSP\(_{13}\) (Fig. 1B) constructs containing three tandem EREs or consensus GC-rich SP1 binding sites linked to the luciferase gene respectively. These constructs in which ER\(\alpha\) or ER\(\alpha\)/SP1 activate their respective promoters represent two of the major genomic pathways of estrogen action in breast cancer cells (Hall et al. 2001, Safe & Kim 2004). The results show that siRNA for MDM2 significantly decreased E\(\alpha\)-induced transactivation in cells transfected with pERE\(_3\) or pSP\(_{13}\) compared with cells transfected with siCT (nonspecific oligonucleotide) or untransfected cells. As a positive control, siGL2 (siRNA for luciferase) also decreased luciferase activity. Endogenous luciferase activity in cells transfected with pSP\(_{13}\) was not affected by siMDM2, suggesting that coactivation of ER\(\alpha\)/specificity protein (SP) may be due to interactions of MDM2 with ER\(\alpha\), not with SP proteins. Figure 1C and D show that MDM2 knockdown (siMDM2) inhibited E\(\alpha\)-induced transactivation in ZR-75 cells transfected with the pERE\(_3\) or pSP\(_{13}\) constructs; similar results were observed in ZR-75 cells transfected with E\(\alpha\)-responsive GC-rich constructs containing promoter inserts from the E2F1 and CAD genes (Wang et al. 1999, Khan et al. 2003, Ngwenya & Safe 2003; data not shown). Moreover, in a mammalian two-hybrid assay in ZR-75 cells, we did not observe SP1–MDM2 interactions (data not shown). Results in Fig. 1E show that siMDM2 decreased siMDM2 protein expression in MCF-7 cells, increased p53 protein expression, and did not affect the levels of SP1 protein.

The effects of overexpression of MDM2 on coactivation of ER\(\alpha\) and ER\(\alpha\)/SP were investigated in MCF-7 cells transfected with pERE\(_3\) (Fig. 2A) or pSP\(_{13}\) (Fig. 2B), and the results showed that MDM2 significantly enhanced ER\(\alpha\) and ER\(\alpha\)/SP-mediated transactivation and similar results were observed in ZR-75 cells (data not shown). Coactivation of ER\(\alpha\) by MDM2 was further investigated in MCF-7 (Fig. 2C) and ZR-75 (Fig. 2D) cells transfected with MDM2, a GAL4-ER\(\alpha\) chimeric protein (pMER), and a construct (GAL4-luc) containing five tandem GAL4 response elements. The results show that E\(\alpha\) significantly induced transactivation in both cell lines and this response was further enhanced by MDM2 expression. Moreover, E\(\alpha\)-induced transactivation in MCF-7 cells transfected with pMER and GAL4-luc was significantly decreased after cotransfection with siMDM2 or siGL2 that knocks down luciferase (Fig. 2E), confirming that MDM2 coactivates ER\(\alpha\)-mediated transactivation.

**MDM2 interacts with ER\(\alpha\)**

It was previously reported that in a mammalian two-hybrid assay in Saos-2 cells using pM-ER\(\alpha\) and VP-MDM2, E\(\alpha\) induced transactivation (interaction); however, in GST pull-down studies ER\(\alpha\) interacted with MDM2 in the presence or absence of ligand (Saji et al. 2001). Results in Fig. 3A show that in mammalian two-hybrid assays in ZR-75 cells, there was increased transactivation in cells transfected with pM-DM2 and VP-ER\(\alpha\) compared with cells transfected with pM-DM2 and VP and this interaction did not require the addition of E\(\alpha\). Moreover, in coimmunoprecipitation experiments with in vitro expressed \(^{35}\)S-labeled ER\(\alpha\) and MDM2 (Xpress-tagged), both proteins interacted in the presence or absence of E\(\alpha\) (Fig. 3B). The interactions of ER\(\alpha\) and MDM2 in living cells were also investigated by FRET in cells transfected with a
**Figure 2** MDM2 coactivates ERα and ERα/SP-dependent transactivation. MCF-7 cells were treated with DMSO or E2, transfected with pERE3 (A) or pSP13 (B) and different amounts of MDM2 expression plasmid, and luciferase activity was determined as described in the section ‘Materials and methods’. The effects of MDM2 expression in MCF-7 (C) and ZR-75 (D) cells or MDM2 knockdown in MCF-7 (E) cells on activation of pM-ERα. The cells were treated with DMSO or 10 nM E2, transfected with pMER and MDM2 expression plasmid, a GAL4-luc reporter construct, and oligonucleotides (as indicated); luciferase activation was determined as outlined in the section ‘Materials and methods’. The results are expressed as means ± s.e.m. for at least three replicate determinations for each treatment group as significant (P<0.05) coactivation by MDM2 (*) and inhibition by siMDM2 or siGL2 (**) are indicated.

CFP-MDM2 construct and a YFP-ERα construct. In preliminary experiments, we showed that similar to MDM2, ECFP-MDM2 also enhanced E2-dependent transactivation in ZR-75 cells transfected with pM-ERα/GAL4-luc (Fig. 3C). FRET analysis was determined in MCF-7 cells transfected with CFP-MDM2 and YFP-ERα (Fig. 3D). The FRET efficiencies obtained are illustrated in Fig. 3E and show that E2 significantly enhanced this response, indicating that although both proteins directly interact in the absence of E2, treatment with hormone clearly enhances this interaction and facilitates the energy transfer between the CFP and YFP moieties in both proteins. As a positive control for this experiment, we also show that E2 enhances YFP-ERα interactions with CFP-SP1 as previously reported (Kim et al. 2005). There was clearly a parallel between the significant effects of E2 on FRET efficiencies associated with YFP-ERα–CFP-SP1 and YFP-ERα–CFP-MDM2 and the E2-independent interaction of ERα with both SP1 (Kim et al. 2005) and MDM2 (Fig. 3A and B) in coimmunoprecipitation experiments.

MDM2 contains several domains that interact with other proteins and also a zinc finger and a C-terminal RING finger domain that functions as an E3-ubiquitin ligase (Ashcroft et al. 1999, Kubbata et al. 1999). We initially examined the interactions of wild-type and deletion variants of MDM2 (Xpress-tagged) with ERα, and Fig. 4A illustrates the electrophotographic mobilities and interactions between 35S-labeled ER and 35S-labeled wild-type MDM2 and variants expressing amino acids 1–342 (MDM2(1–342 aa)), 134–342 (MDM2(134–342 aa)), and 134–490 (MDM2(134–490 aa)). Coimmunoprecipitation experiments showed that ERα interacted with wild-type MDM2 (lane 7), MDM2 (1–342 aa) (lane 8), MDM2 (134–490 aa) (lane 10) but not with MDM2 (134–342 aa) (lane 9). Lanes 1–6 illustrate the 35S-labeled proteins alone. Thus, ERα interacts with both C- and N-terminal domains of MDM2 but not with the 134–342 aa region, which binds CBP/p300 (Grossman et al. 1998). In contrast, coactivation studies in ZR-75 cells transfected with pM-ERα showed that only wild-type, but not the deletion variants of MDM2, coactivated ERα (Fig. 4B). These results suggest that multiple regions of MDM2 are required for coactivation of ERα.

**MDM2 enhances interactions of ERα with steroid receptor coactivators**

Steroid receptor coactivators (SRCs), mediator proteins, and p300 associate with ER as complexes that interact cyclically with E2-responsive gene promoters, and MDM2 has been identified as a component of these complexes (Metivier et al. 2003, Reid et al. 2003). The role of MDM2 and its interactions with coactivators has been further investigated in mammalian two-hybrid assays using coactivator–GAL4 chimeras (pM-coactivators), VP-ERα, and GAL4-luc in ZR-75 cells. In cells transfected with pMGRIPwt, VP-ERα and GAL4-luc treatment with E2 induced transactivation; however, E2-dependent interactions were significantly inhibited in cells cotransfected with siMDM2, suggesting that interactions of GRIP (SRC-2) and ERα are mediated, in part, by MDM2 (Fig. 5A). Interactions of GRIP and MDM2 were also investigated in a mammalian two-hybrid assay in ZR-75 cells transfected with pMGRIP/GAL4-luc and VP-MDM2, and the results
show that MDM2 and GRIP do not interact in the presence or absence of E2 (Fig. 5B). However, after cotransfection with ERα, there was a significant increase in transactivation, which was observed in the absence or presence of E2 but was more pronounced in the former case. These results suggest that, although GRIP and MDM2 do not exhibit binding in a two-hybrid assay, the expression of ERα significantly enhanced interactions between GRIP and MDM2. ER–coactivator interactions are dependent, in part, on interactions between
NR-box (LXXLL) motifs in coactivators (Torchia et al. 1997, Voegel et al. 1998) with ERα, and Fig. 5C shows that E2 induces transactivation in ZR-75 cells transfected with VP-ERα and pMGRIP(LXXLL)/GAL4-luc where pMGRIP(LXXLL) is a chimera containing GAL4 fused to aa629–760 from GRIP/SRC-2, which contains an LXXLL motif. E2-dependent interactions of ERα and GRIP(LXXLL) in the mammalian two-hybrid assay were inhibited after cotransfection with siMDM2, suggesting that MDM2 facilitates ERα interactions with the NR-box motif of GRIP. pMGRIP(LXXLL) did not interact with VP-MDM2 in a two-hybrid assay; however, cotransfection with ERα in the presence or absence of E2 enhanced transactivation (Fig. 5D).

These results suggest that ERα enhances MDM2 interactions with the NR-box motif of GRIP.

The role of MDM2 in the interaction of ERα with SRC-1 and SRC-3 (AIB-1) was also investigated in mammalian two-hybrid assays in ZR-75 cells (Fig. 6), and the results were similar to those observed for ERα and GRIP. E2 induced transactivation in cells transfected with pMSRC-1/GAL4-luc plus VP-ERα (Fig. 6A) or pMAIB-1/GAL4-luc plus VP-ERα (Fig. 6B). Cotransfection with siMDM2 inhibited basal and induced activity, and the inhibition was most pronounced for AIB-1–ERα interactions. Interactions of pMSRC-1 and VP-MDM2 (Fig. 6C) or pMAIB-1 and VP-MDM2 (Fig. 6D) were not observed in mammalian two-hybrid assays; however, cotransfection with ERα significantly enhanced transactivation in the absence or presence of E2. The hormone-induced response was more pronounced with pMAIB-1 compared to pMSRC-1; moreover, E2 decreased transactivation in ZR-75 cells transfected with pMSRC-1, VP16-MDM2 and ERα, suggesting that liganded ERα may inhibit SRC-1–MDM2 interactions. These results demonstrate that although MDM2 does not interact with SRCs, this protein plays a key role in enhancing ERα interactions with the SRC coactivators. Results in Fig. 6E demonstrate that E2 also induces transactivation in ZR-75 cells transfected pMp300/GAL4-luc and VP-ERα; however, siMDM2 slightly enhances both basal and E2-induced activity. These results demonstrate the specificity of the SRC–ERα–MDM2 compared to that observed for p300–ERα–MDM2 interactions where MDM2 plays a key role in coactivator ERα interactions but not p300–ERα interactions. The ‘constitutive’ inhibitory effect may be due to the competitive binding of both ERα and MDM2 to p300 (Hanstein et al. 1996, Grossman et al. 1998).

### MDM2 enhances E2-dependent activation of pS2 and E2F1 and cell proliferation

The functional effects of MDM2 on hormone-induced gene expression were investigated in p53-expressing ZR-75 cells and T47D cells that do not express functional p53. In ZR-75 (Fig. 7A) and T47D (Fig. 7B) cells transfected with siMDM2, induction of E2F1 protein expression was decreased after the loss of MDM2. The role of MDM2 in hormone-induced expression of E2F1 and pS2 mRNA levels in ZR-75 (Fig. 7C) and T47D (Fig. 7D) cells was also determined, and the hormone-induced responses were significantly decreased in cells transfected with siMDM2. Moreover, using a similar approach, knockdown of MDM2 by RNA interference in T47D cells decreased induction of CAD and cyclin D1 by E2 (data not shown). Since p53 inhibits estrogen responsiveness, it is possible that the loss of hormone-induced transactivation in breast cancer cells transfected with siMDM2 may be due, in part, to activation of...
Coactivators and other coregulatory proteins play a critical role in hormone receptor-dependent gene expression, and these nuclear proteins are essential factors for ligand-induced transcriptional activation (Blanco et al. 1998, O’Malley 2007). Initial studies describing coactivation of nuclear receptors by SRCs demonstrated several essential features of coactivator function. These included identification of NR-boxes required for specific coactivator–receptor interactions with promoter DNA, and interactions of coactivators with multiple domains of nuclear receptors and with other nuclear cofactors (Blanco et al. 1998, O’Malley 2007). This complexity associated with SRCs has been further magnified by ongoing studies that have identified many other classes of coactivators, which manifest their activities through ATP-dependent chromatin modeling, histone methylation, or modification of receptors through ubiquitination or sumoylation (Blanco et al. 1998, O’Malley 2007, O’Malley & Kumar 2009).

The interactions of different functional classes of nuclear factors in ERz-mediated transcriptional activation have been extensively investigated in chromatin immunoprecipitation (ChIP) assays, which demonstrate an ordered cycling of distinct cofactor/ERz complexes on and off the E2-responsive promoters (Shang et al. 2000, Burakov et al. 2002, Metivier et al. 2003, Reid et al. 2003). MDM2, which exhibits E3-ubiquitin ligase activity, is involved in this cycling process, and previous studies have shown that MDM2 overexpression coactivates ERz-dependent transcriptional activity in cells transfected with ERE-promoter constructs (Saji et al. 2001). Research in this laboratory and others have demonstrated that E2 also activates genes in breast cancer cells through ERz/SP interactions with GC-rich promoters (O’Malley 2007), and we have been investigating the coactivation of ERz and ERz/SP in breast cancer cells transfected with pEREz and pSP1z respectively (Kim et al. 2003, Wu et al. 2004, Lee et al. 2005, Lee & Safe 2007). Vitamin D interacting protein 150 (DRIP150) is a mediator complex protein (Koh et al. 2002, Kouzmenko et al. 2004), which coactivates ERz and ERz/SP1, and this...
Figure 6 Effects of MDM2 on coactivation of ERα by other coactivators and p300. ZR-75 cells were treated with DMSO or 10 nM E2, transfected with pMSRC-1/VP-ERα (A) or pMAIB-1/VP-ERα (B), GAL4-luc and siCT or siMDM2 oligonucleotides, and luciferase activity was determined as outlined in the section ‘Materials and methods’. The effects of ERα on MDM2 coactivator interactions. ZR-75 cells were treated with DMSO or 10 nM E2, transfected with pMSRC-1/VP-MDM2 or pMAIB-1/VP-MDM2, empty vectors or ERα and GAL4-luc, and luciferase activity was determined as described in the section ‘Materials and methods’. (E) The effect of MDM2 knockdown on ERα–p300 interactions. ZR-75 cells were treated with DMSO or 10 nM E2, transfected with pMmp300/VP-ERα and GAL4-luc, and luciferase activity was determined as outlined in the section ‘Materials and methods’. The results are expressed as means ± S.E.M. for at least three replicate determinations for each treatment group and significantly (P<0.05) enhanced activity after transfections with ERα (*) and decreased activity after transfection with siMDM2 (**) are indicated.

Involves an α-helical NIFSEVRVYN (amino acids 795–804) motif within a 23 amino acid sequence (789–811) in the central region of DRIP150 that does not contain an LXXLL box (Lee et al. 2005, Lee & Safe 2007). DRIP150 had minimal effects on SP-dependent transactivation and coactivated ERα and ERα/SP1 primarily through interactions with ERα (Lee & Safe 2007). In this study, we demonstrate that E2-induced transactivation in breast cancer cells transfected with pSP13 or pERE3 constructs (Fig. 2A and B). We also observed that in ZR-75 and T47D cells transfected with siMDM2, there was a significant decrease in hormone-induced protein and mRNA levels (Fig. 7), demonstrating a role for MDM2 in E2-induced gene expression. These results confirm coactivation of ERα by MDM2 as previously reported (Saji et al. 2001) and also show that MDM2 coactivates ERz/SP1. MDM2 did not interact with SP1 and knockdown or overexpression of MDM2 did not affect SP-dependent transactivation (Figs 1A and B and 2A and C), suggesting that coactivation of ERα and ERα/SP is primarily associated with direct interactions between MDM2 and ERα.

MDM2 interacts with ERα in the presence or absence of E2 (Fig. 3A and B) and E2 also enhances ERα–MDM2 interactions in living cells as determined by FRET analysis (Fig. 3D and E). It is clear from ChIP assays that ERα, MDM2, and other nuclear coregulatory proteins cycle on and off E2-responsive gene promoters in breast cancer cells, and there is also evidence that specific subsets of coactivators may be selectively recruited to the pS2 promoter (Metivier et al. 2003). Since constitutively expressed and transiently overexpressed MDM2 activated ERα and ERα/SP1, it is possible that this protein may also act in concert with other nuclear cofactors such as the SRCs. Previous studies have demonstrated coactivation of ERα by SRCs (Blanco et al. 1998, Vassilev et al. 2004, O’Malley 2007) and corecruitment of MDM2 and SRCs to E2-responsive gene promoters and, therefore, we hypothesized that MDM2 acts, in part, through facilitating SRC–ERα interactions. Results in Figs 5 and 6 demonstrate that interactions of pMSRCs with VP-ERα are E2 dependent, and similar results were observed with interactions of VP-ER with the GRIP1 LXXLL box (GAL4-GRIP(LXXLL)) (Fig. 5C). These hormone-dependent ER–SRC interactions were not surprising; however, using RNA interference with siMDM2, it was evident that MDM2 facilitated ERα–SRC (Figs 5A and 6A, and C) but not ERα–p500 (Fig. 6E) interactions in a mammalian two-hybrid assay. Moreover, it was also apparent in mammalian two-hybrid assays in which cells were transfected with pMSRC and VP16-MDM2 that MDM2 did not directly interact with coactivators unless ERα was also overexpressed, and this resulted in increased transactivation in the presence or absence of E2 (Figs 5B and 6B and D).

These results suggest a model for MDM2 coactivation of ERα or ERα/SP1 in which MDM2 acts alone or in combination with SRCs to enhance transactivation. This resembles, in part, a similar model proposed for β-catenin, which enhances nuclear receptor or transcription factor-mediated transactivation alone and in combination with other coactivators (Koh et al. 2002, Kouzmenko et al. 2004, Li et al. 2004, Yang et al. 2006).
Figure 7 MDM2 regulates ERα- and E2-dependent genes and responses in breast cancer cells. The effects of siMDM2 on E2F1 protein levels in ZR-75 (A) and T47D (B) cells. Cells were transfected with siCT (nonspecific) or siMDM2, treated with 10 nM E2 for 0, 6, or 12 h, and whole cell lysates were analyzed for E2F1 and β-actin (loading control) by western blots as described in the section ‘Materials and methods’. The effects of siMDM2 on E2F1 and pS2 mRNA levels in ZR-75 (C) and T47D (D) cells. Cells were transfected with siCT (nonspecific) or siMDM2, treated with DMSO or 10 nM E2 for the indicated times, and mRNA levels were determined by real-time PCR as described in the section ‘Materials and methods’. The results are expressed as means ± S.E.M. for three replicate determinations and significant (P < 0.05) induction by E2 (*) and inhibition by siMDM2 (**) are indicated. (E) The effects of Nutlin. T47D or ZR-75 cells were treated with DMSO or 10 nM E2 in the presence or absence of 5 µM Nutlin and analyzed for E2F1 and β-actin (loading control) by western blots. (F) siMDM2 inhibits growth and hormone-induced cell proliferation. MCF-7 or ZR-75 cells were transfected with siCT or siMDM2, treated with DMSO or 10 nM E2, and cells were counted at various time points as described in the section ‘Materials and methods’. The results are expressed as means ± S.E.M. for three replicate determinations and significant induction by E2 (compared to DMSO) (*) and inhibition by siMDM2 (**) are indicated.
For example, β-catenin enhanced interactions between LEF1 (GAL4-LEF1) and GRIP1 (VP-GRIP), and this was primarily due to coactivation and interactions of β-catenin with LEF1 but not with GRIP1. Similarly, this study shows that MDM2 enhanced interactions between ERα and SRCs, and this was primarily associated with coactivation and interactions with ERα since MDM2 and SRCs did not interact. The cooperative coactivation of nuclear receptors by coactivators and other nuclear factors is highly variable. For example, CARML and p300 enhanced GRIP1-dependent coactivation of ERα and the former proteins interact with GRIP1 but not with ERα (Chen et al. 2000). In contrast, the model for coactivation of ERα and ERα/SP1 by SRCs and MDM2 primarily involves MDM2 interactions with ERα and not with SRCs.

Current studies are investigating the role of MDM2 in regulating expression of E2-responsive genes with ERα and GC-rich promoters and determining their cyclical interactions with gene promoters and other coactivators using ChIP assays. Our results clearly demonstrate that MDM2 enhances ER-dependent transactivation and cell proliferation (Fig. 7), and in transactivation assays, the loss of hormone responsiveness in cells transfected with siMDM2 was p53 independent (data not shown). Cotransfection of cells with siMDM2 alone or siMDM2 plus sip53 gave similar results, whereas knockdown of p53 alone (sip53) slightly enhanced hormone-induced transactivation, and this was consistent with a recent study (Akaogi et al. 2009) and a report showing that p53 decreases hormone-induced transactivation (Liu et al. 1999). In breast cancer, the potential prognostic significance of MDM2 or an MDM2 promoter polymorphism (SNP309) that enhances MDM2 expression has been inconsistent (Wilkening et al. 2007). However, examination of the publically available Nederlands Kanker Instituut (NKI) gene expression data from ER-positive breast cancer patients (van de Vijver et al. 2002) shows that low-MDM2 levels predict a higher overall and relapse-free survival compared with patients with high-MDM2 levels (data not shown) and this observation is consistent with the results of this study showing the critical role of MDM2 in hormone-induced gene expression and growth of ER-positive breast cancer cells, suggesting that MDM2 inhibitors may be efficacious for treatment of ER-positive breast cancer patients. However, it should also be noted that the loss of MDM2 and the decreased MCF-7 and ZR-75 cell proliferation (Fig. 7F) may also be due to the parallel activation of p53 after MDM2 knockdown.

Funding

This research was supported by the National Institutes of Health and is gratefully acknowledged (ES04917).

References

Cahilly-Snyder L, Yang-Feng T, Francke U & George DL 1987 (SNP309) that enhances MDM2 expression has been identified. EMBO Journal 6 4009–4016. (doi:10.1002/j.1092-235X.1987.t00001490)
Fahkarzadeh SS, Trusko SP & George DL 1991 Tumorigenic potential of MDM2 or an MDM2 promoter polymorphism (SNP309) that enhances MDM2 expression has been inconsistent (Wilkening et al. 2007). However, examination of the publically available Nederlands Kanker Instituut (NKI) gene expression data from ER-positive breast cancer patients (van de Vijver et al. 2002) shows that low-MDM2 levels predict a higher overall and relapse-free survival compared with patients with high-MDM2 levels (data not shown) and this observation is consistent with the results of this study showing the critical role of MDM2 in hormone-induced gene expression and growth of ER-positive breast cancer cells, suggesting that MDM2 inhibitors may be efficacious for treatment of ER-positive breast cancer patients. However, it should also be noted that the loss of MDM2 and the decreased MCF-7 and ZR-75 cell proliferation (Fig. 7F) may also be due to the parallel activation of p53 after MDM2 knockdown.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.


O’Malley BW 2007 Coregulators: from whence came these "master genes". *Molecular Endocrinology* **21** 1009–1013. (doi:10.1210/me.2007-0012)


Received in final form 8 December 2010
Accepted 17 December 2010
Made available online as an Accepted Preprint 17 December 2010